Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Depression
FDA approves Cymbalta for the treatment of depression
September 5th, 2004
The U.S. Food and Drug Administration (FDA) has approved Cymbalta (duloxetine HCl) judging it a safe and effective treatment for major depressive disorder, Eli Lilly and Co. (LLY) announced. Cymbalta, a balanced reuptake inhibitor of serotonin and norepinephrine, has been studied in more than 6,000 adults with major depression worldwide. Its approval gives healthcare professionals and patients a long-awaited new option for treating the broad range of emotional and physical symptoms of depression. Today, only 25-35% of patients treated for depression in clinical studies experience relief from all of their disease symptoms. "Depression is a whole-body...
Source: Medical Letter on the CDC & FDA (2004-09-05)
|
